A Multicenter, Randomized, Double-Blind, Placebo-controlled, Phase III Study to Assess the Efficacy and Safety of KN046 Combined With Platinum-containing Chemotherapy Versus Placebo Combined With Platinum-containing Chemotherapy in First Line Advanced Squamous Non-small Cell Lung Cancer Subjects (ENREACH-L-01)
Latest Information Update: 07 Nov 2023
Price :
$35 *
At a glance
- Drugs Erfonrilimab (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms ENREACH-L-01; ENREACH-LUNG-01
- Sponsors Jiangsu Alphamab Biopharmaceuticals
- 16 Nov 2021 Status changed from recruiting to active, no longer recruiting.
- 15 Sep 2020 Planned End Date changed from 30 Aug 2020 to 30 Aug 2023.
- 15 Sep 2020 Planned primary completion date changed from 30 Aug 2020 to 30 Aug 2022.